Admission Date:  [**2161-10-18**]              Discharge Date:   [**2161-11-5**]  Date of Birth:  [**2099-7-2**]             Sex:   M  Service: MEDICINE  Allergies: Patient recorded as having No Known Allergies to Drugs  Attending:[**First Name3 (LF) 3276**] Chief Complaint: dyspnea, low grade fever  Major Surgical or Invasive Procedure: pleurex catheter drainage EGD   History of Present Illness: Mr. [**Known lastname 42603**] is a 62 year old male with a h/o metastatic large cell lung cancer to bone c/b recurrent malignant pleural effusion requiring pleurex catheter placement, HIV (CD4 535) on HAART, htn who presented to the ED with pleuritic CP and dyspnea which has been his long standing issues.
CXR revealed moderate to large left sided pleural effusion with pleurex drain and minimal interval changes.
His temp subsequently went to 100.5 although he [**Doctor First Name 1638**] any neck stiffness, photophobia, cough, nausea, vomiting, diarrhoea, dysuria or rash.
He was cultured and started on vanco and zosyn.
Past Medical History: [**7-/2159**]: Diagnosed with non small cell lung cancer by CT guided biopsy [**2159-9-20**]: PET scan with low-attenuation lesion in the left lobe of the thyroid gland measuring 25 x 7 mm in addition to markedly FDG avid left upper lobe mass consistent with known cancer and FDG avid prominent bilateral axillary lymphadenopathy suspicious for metastatic disease, but no pathologically enlarged infraclavicular lymph nodes.
Further staging and treatment were deferred until the patient was stabilized on HAART therapy.
He was initially seen by infectious disease doctors [**Last Name (NamePattern4) **] [**2160-1-10**] and was started on HAART therapy in 01/[**2160**].
[**2160-8-6**]: Bronchoscopy, mediastinoscopy, and pleural drainage and talc pleurodesis by Dr. [**Last Name (STitle) **].
He was started on carboplatin and gemcitabine on [**2160-8-28**] he has completed 4 cycles.
[**2160-12-5**]: MR [**Name13 (STitle) **] with L1 lesion .
- History of appendicitis status post appendectomy in [**2126**].
He received transfusions potentially around the time of his appendectomy in [**2126**].
Pertinent Results: [**2161-10-18**]  WBC-10.7  Hgb-9.8* Hct-30.9*   Plt Ct-577* [**2161-10-19**]  WBC-3.6*#  Hgb-8.6* Hct-25.8*   Plt Ct-397 [**2161-10-19**]  WBC-2.3*  Hgb-9.6* Hct-29.3*   Plt Ct-379 [**2161-10-20**]  WBC-1.5*  Hgb-9.0* Hct-27.7*   Plt Ct-319 [**2161-10-21**]  WBC-2.1*  Hgb-9.1* Hct-27.4*   Plt Ct-257 [**2161-10-22**]  WBC-2.9*  Hgb-8.6* Hct-26.6*   Plt Ct-220 [**2161-10-23**]  WBC-3.8*  Hgb-8.9* Hct-27.3*   Plt Ct-169 [**2161-10-24**]  WBC-3.9*  Hgb-8.2* Hct-25.4*   Plt Ct-167 [**2161-10-24**]  WBC-4.0  Hgb-8.5* Hct-26.9*   Plt Ct-153 [**2161-10-25**]  WBC-4.5  Hgb-7.4* Hct-21.9*   Plt Ct-178 [**2161-10-26**]  WBC-5.5  Hgb-7.9* Hct-24.0*   Plt Ct-182 [**2161-10-27**]  WBC-6.4  Hgb-9.2* Hct-26.7*   Plt Ct-172 [**2161-10-28**]  WBC-7.0  Hgb-9.8* Hct-28.6*   Plt Ct-227 [**2161-10-29**]  WBC-8.5  Hgb-9.6* Hct-28.7*   Plt Ct-279 [**2161-10-30**]  WBC-8.3  Hgb-9.4* Hct-29.7*   Plt Ct-359 [**2161-10-31**]  WBC-7.8  Hgb-9.8* Hct-29.6*   Plt Ct-458* [**2161-11-1**]  WBC-7.9  Hgb-9.3* Hct-28.5*   Plt Ct-521* [**2161-11-2**]  WBC-5.8  Hgb-9.7* Hct-29.3*   Plt Ct-595* [**2161-11-4**]  WBC-6.8  Hgb-9.3* Hct-29.4*   Plt Ct-676* [**2161-11-5**]  WBC-7.5  Hgb-9.0* Hct-28.0*   Plt Ct-656*  [**2161-10-28**]   WBC-7.0 Lymph-43* Abs [**Last Name (un) **]-3010 CD3%-78 Abs CD3-2339* CD4%-16 Abs CD4-483 CD8%-61 Abs CD8-1824* CD4/CD8-0.3*  [**2161-10-18**]   UreaN-11 Creat-1.2 Na-136 K-4.6 Cl-96 HCO3-28 AnGap-17 [**2161-10-19**]   UreaN-10 Creat-1.1 Na-139 K-3.8 Cl-102 HCO3-30 AnGap-11 [**2161-10-20**]   UreaN-6 Creat-1.2 Na-140 K-3.7 Cl-103 HCO3-30 AnGap-11 [**2161-10-21**]   UreaN-11 Creat-1.4* Na-142 K-3.8 Cl-102 HCO3-31 AnGap-13 [**2161-10-22**]   UreaN-9 Creat-1.4* Na-141 K-3.7 Cl-100 HCO3-31 AnGap-14 [**2161-10-23**]   UreaN-8 Creat-1.6* Na-141 K-4.0 Cl-104 HCO3-30 AnGap-11 [**2161-10-23**]   UreaN-8 Creat-1.6* Na-138 K-3.9 Cl-100 HCO3-29 AnGap-13 [**2161-10-24**]   UreaN-7 Creat-1.7* Na-139 K-3.6 Cl-101 HCO3-30 AnGap-12 [**2161-10-25**]   UreaN-7 Creat-1.7* Na-138 K-4.0 Cl-100 HCO3-30 AnGap-12 [**2161-10-26**]   UreaN-10 Creat-2.0* Na-139 K-4.0 Cl-100 HCO3-31 AnGap-12 [**2161-10-27**]   UreaN-13 Creat-2.0* Na-140 K-4.2 Cl-103 HCO3-29 AnGap-12 [**2161-10-28**]   UreaN-10 Creat-2.0* Na-141 K-4.0 Cl-102 HCO3-30 AnGap-13 [**2161-10-29**]   UreaN-11 Creat-2.1* Na-143 K-4.0 Cl-105 HCO3-26 AnGap-16 [**2161-10-30**]   UreaN-11 Creat-2.3* Na-143 K-4.2 Cl-105 HCO3-29 AnGap-13 [**2161-10-31**]   UreaN-11 Creat-2.3* Na-141 K-4.2 Cl-105 HCO3-28 AnGap-12 [**2161-11-1**]   UreaN-12 Creat-2.3* Na-143 K-4.3 Cl-105 HCO3-30 AnGap-12 [**2161-11-2**]   UreaN-11 Creat-2.3* Na-145 K-4.3 Cl-105 HCO3-29 AnGap-15 [**2161-11-3**]   UreaN-9 Creat-1.9* Na-143 K-4.1 Cl-104 HCO3-29 AnGap-14 [**2161-11-4**]   UreaN-8 Creat-2.1* Na-147* K-4.3 Cl-108 HCO3-31 AnGap-12 [**2161-11-5**]   UreaN-9 Creat-1.8* Na-145 K-4.2 Cl-105 HCO3-32 AnGap-12  [**2161-10-24**]  ALT-97* AST-89* LD(LDH)-505* CK(CPK)-97 AP-288* Amylase-93 TotBili-5.1* [**2161-10-24**]  CK(CPK)-102 [**2161-10-25**]  ALT-79* AST-66* LD(LDH)-478* CK(CPK)-88 AP-246* Amylase-80 TotBili-4.4* DirBili-0.2 IndBili-4.2 [**2161-10-26**]  ALT-64* AST-53* AP-244* TotBili-4.2* [**2161-10-27**]  ALT-50* AST-43* LD(LDH)-497* AP-227* Amylase-78 TotBili-4.5* [**2161-10-28**]  ALT-41* AST-41* LD(LDH)-514* AP-230* TotBili-4.4* [**2161-10-29**]  ALT-37 AST-43* AP-236* TotBili-3.1* [**2161-10-30**]  ALT-58* AST-79* LD(LDH)-486* AP-406* TotBili-1.5 [**2161-10-31**]  ALT-44* AST-51* LD(LDH)-483* AP-371* TotBili-0.7 [**2161-11-1**]  ALT-45* AST-61* LD(LDH)-469* AP-402* TotBili-0.4 [**2161-11-4**]  ALT-86* AST-165* LD(LDH)-619* AP-465* TotBili-0.4 [**2161-11-5**]  ALT-59* AST-69* LD(LDH)-607* AP-409* TotBili-0.4  [**2161-10-24**]  CK-MB-2 cTropnT-<0.01 [**2161-10-24**]  CK-MB-2 cTropnT-<0.01 [**2161-10-25**]  CK-MB-2 cTropnT-<0.01 [**2161-10-28**]  Type-ART pO2-92 pCO2-26* pH-7.66* calTCO2-30 Base XS-9  [**2161-10-28**]  Type-ART pO2-26* pCO2-37 pH-7.53* calTCO2-32* Base XS-6 [**2161-10-29**]  Type-[**Last Name (un) **] pO2-43* pCO2-47* pH-7.45 calTCO2-34* Base XS-7 [**2161-10-30**]  Type-[**Last Name (un) **] pO2-154* pCO2-46* pH-7.45 calTCO2-33* Base XS-7 C [**2161-10-28**]  Lactate-1.1 Na-143 K-3.7 Cl-102 [**2161-10-28**]  Lactate-2.1* Na-144 K-3.8 Cl-101  [**2161-10-21**]  URINE Hours-RANDOM Creat-31 Na-31 K-13 Cl-30 [**2161-10-24**]  URINE Hours-RANDOM Creat-31 Na-24 [**2161-10-28**]  URINE Hours-RANDOM Creat-30 Na-49 K-16 Cl-39 [**2161-10-30**]  URINE Hours-RANDOM UreaN-126 Creat-45 Na-32 Phos-6.8 [**2161-10-28**]  URINE Osmolal-160 [**2161-10-30**]  URINE Osmolal-153 [**2161-10-20**]  PLEURAL WBC-600* RBC-8125* Polys-0 Lymphs-95* Monos-5* [**2161-10-21**]  PLEURAL WBC-889* RBC-[**Numeric Identifier 42605**]* Polys-1* Lymphs-89* Monos-6* Eos-1* Meso-2* Macro-1* [**2161-11-5**]  PLEURAL WBC-650* RBC-[**Numeric Identifier 42606**]* Polys-7* Lymphs-91* Monos-2* [**2161-10-20**]  PLEURAL TotProt-3.9 LD(LDH)-527 [**2161-10-20**]  PLEURAL TotProt-3.4 LD(LDH)-447 [**2161-10-21**]  PLEURAL TotProt-3.7 Glucose-119 LD(LDH)-430  CXR [**10-18**] IMPRESSION: Moderate to large left pleural effusion with related atelectasis unchanged.
2. s/p cholecystectomy.
ECHO: No vegetations EGD: mucosal erythema c/w gastritis  pleural fluid at discharge: GRAM STAIN (Final [**2161-11-5**]):       2+   (1-5 per 1000X FIELD):   POLYMORPHONUCLEAR LEUKOCYTES.
ANAEROBIC CULTURE (Preliminary):    NO GROWTH   Brief Hospital Course: 62 year old male with a h/o metastatic large cell lung cancer to bone c/b recurrent malignant pleural effusion requiring pleurex catheter placement, HIV (CD4 535) on HAART, htn who presented with dyspnea, unchanged pleural effusion on cxr and low grade fever.
The patient was treated with levofloxacin and was afebrile.
See above for pleural fluid analysis at discharge.
The patient will continue to receive thrice weekly pleurex drainage via VNA at home.
It resolved with ativan and morphine.
He was started on [**Hospital1 **] Klonipin with good effect.
HAART was stopped for [**Last Name (un) **], elevated LFTs.
# Hypertension: controlled well with amlodpine  # Depression/suicidal ideation: iniatlly followed by pscyh for question of suicidal ideation on admission but this appears to have been a misunderstanding.
Code- full  Medications on Admission: amlodipine 10 mg daily atazanavir 300 mg daily Truvada 200mg/300mg daily ritonivir 100 mg daily alimenta Q3weeks folic acid 1 mg daily ibuprofen 800 mg TID morphine SR 15 mg [**Hospital1 **] oxycodone 5-10 mg Q4H prn ranitidine 150 mg daily colace/senna compazine 10 mg prn lactulose prn albuterol prn  Discharge Medications: 1.
Amlodipine 5 mg Tablet Sig: Two (2) Tablet PO DAILY (Daily).
Folic Acid 1 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Oxycodone 5 mg Tablet Sig: 1-2 Tablets PO Q4H (every 4 hours) as needed for pain.
Albuterol Sulfate 2.5 mg /3 mL (0.083 %) Solution for Nebulization Sig: One (1)  Inhalation Q6H (every 6 hours) as needed for wheeze.
Docusate Sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 times a day).
Senna 8.6 mg Tablet Sig: One (1) Tablet PO BID (2 times a day).
Clonazepam 0.5 mg Tablet Sig: One (1) Tablet PO twice a day.
Ranitidine HCl 150 mg Capsule Sig: One (1) Capsule PO once a day.
Compazine 10 mg Tablet Sig: One (1) Tablet PO once a day as needed for nausea.
Lactulose 10 gram Packet Sig: One (1)  PO once a day.
Disp:*30 packets* Refills:*2*   Discharge Disposition: Home With Service  Facility: [**Hospital 119**] Homecare  Discharge Diagnosis: Primary Diagnosis: metastatic large cell lung cancer HIV/AIDS  Secondary Diagnoses: # stage IIIB large cell lung cancer metastatic to bone - started Alimenta [**2161-7-16**] # HIV, CD4 [**6-13**] 535, VL undetectable - diagnosed in [**2142**] - re-initiated HAART on [**2160-2-28**] # chronic malignant pleural effusion s/p talc pleurodesis [**8-12**] with pleurex catheter placed [**1-12**] for recurrent effusion # Hypertension # Positive PPD-negative AFB [**1-11**]-s/p 6 months Rifampin in [**2148**].
# Hepatitis B # s/p cholecystectomy on [**2161-4-1**] # h/o appendicitis status post appendectomy in [**2126**] # Sellar mass seen on MRI most recently on [**2160-8-4**] - a stable appearance of the intra and suprasellar mass - nonfunctioning mass as worked up by endocrinology # Low back pain     Discharge Condition: stable and improved   Discharge Instructions: You were admitted to the hospital for shortness of breath.
The following changes have been made to your medications: please do not take your HIV medications until you meet with Dr. [**Last Name (STitle) 7443**]: atazanavir Truvada ritonivir  See below for follow up appointments.
